Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder with Comorbid Major Depressive Disorder: A Case Series of Eight Patients
Research Square September 26, 2025 Soria López, Cinto Segalàs, Eva Real et al.
In eight adults with treatment-resistant obsessive-compulsive disorder and major depression, adding intranasal esketamine to their existing treatment for 12 weeks reduced depressive symptoms by 48.8% and obsessive-compulsive symptoms by 30.4%. Four participants (50%) showed a depression response, with two (25%) achieving remission; three (37.5%) met the response criterion for OCD. The findings suggest esketamine may have dual benefits for both conditions, but controlled trials are needed to confirm these preliminary results.